Core Viewpoint - Dongwu Securities initiates coverage on Meili Tianyuan Medical Health (02373) with a "Buy" rating, highlighting its unique "Double Beauty + Double Health" ecosystem, proven acquisition integration capabilities, and excellent operational efficiency, which are expected to drive significant growth in the industry [1] Group 1: Company Overview - The company, established in 1993, has developed a comprehensive beauty and health management service system that includes traditional beauty, medical beauty, and sub-health assessment and intervention [2] - It operates four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its market position through acquisitions of Nairui'er and Siyuanli, forming a synergistic ecosystem of "life beauty + medical beauty + traditional health + sub-health medical" [2] Group 2: Financial Performance - The company demonstrates strong growth resilience, with revenue increasing from 1.503 billion in 2020 to 2.572 billion in 2024, representing a compound annual growth rate (CAGR) of 11.3% [3] - In the first half of 2025, revenue accelerated to 1.459 billion, a year-on-year increase of 28.2% [3] - Net profit attributable to shareholders rose from 151 million in 2020 to 228 million in 2024, with a year-on-year growth of 34.9% in the first half of 2025, reaching 156 million [3] - Gross margin improved to 49.33% in the first half of 2025, while net margin optimized to 10.67%, reflecting effective cost control and an increase in high-margin business [3] - The company commits to a dividend payout ratio of no less than 50% of net profit attributable to shareholders over the next three years, indicating strong dividend levels [3] Group 3: Industry Outlook - The traditional beauty, light medical beauty, and sub-health sectors are expected to continue expanding, with projected market sizes of 640.2 billion, 415.7 billion, and 29 billion respectively by 2030 [4] - As young consumers increasingly prioritize standardized services and stable experiences, leading companies are expected to gain significant advantages, leading to higher market concentration [4] - The overlapping consumer base in traditional beauty and light medical beauty allows for effective cross-referrals, enhancing customer conversion rates [4] Group 4: Business Synergy and Growth Strategy - The company's core business model exhibits strong synergy, utilizing its extensive and trusted life beauty services as a front-end traffic source to efficiently convert to high-ticket medical beauty and sub-health services, with a cross-business conversion rate of 28.7% in 2024 [5] - The company employs a strategy of "directly operated stores as benchmarks, franchising for coverage," leading to rapid expansion of its store network, which is expected to reach 554 by the end of 2024 [5] - The company has a robust target selection system and post-acquisition digital integration capabilities, as evidenced by the significant improvement in net margin following the acquisition of Nairui'er, showcasing its strong integration and empowerment capabilities [5]

Core Viewpoint - Dongwu Securities initiates coverage on Meili Tianyuan Healthcare (02373) with a "Buy" rating, highlighting its unique "Double Beauty + Double Health" ecological model, proven acquisition integration capabilities, and excellent operational efficiency, which are expected to drive sustained industry leadership and significant growth [1] Group 1: Company Overview - Established in 1993, the company has developed a comprehensive beauty and health management service system covering traditional beauty, medical beauty, and sub-health assessment and intervention [2] - The company owns four major brands: Meili Tianyuan, Beili Shi, Xiuker, and Yanyuan, and has strengthened its industry position through acquisitions of Nairui'er and Siyuanli, forming a synergistic ecological closed loop [2] Group 2: Financial Performance - The company demonstrates strong growth resilience, with revenue increasing from 1.503 billion in 2020 to 2.572 billion in 2024, representing a compound annual growth rate (CAGR) of 11.3% [3] - In the first half of 2025, revenue accelerated to 1.459 billion, a year-on-year increase of 28.2% [3] - Net profit attributable to shareholders rose from 151 million in 2020 to 228 million in 2024, with a year-on-year growth of 34.9% in the first half of 2025, reaching 156 million [3] - Gross margin improved to 49.33% in the first half of 2025, while net margin optimized to 10.67%, reflecting effective cost control and a higher proportion of high-margin business [3] - The company commits to a dividend payout ratio of no less than 50% of net profit attributable to shareholders over the next three years, indicating strong dividend levels [3] Group 3: Industry Outlook - The traditional beauty, light medical beauty, and sub-health sectors are expected to see long-term growth, with market sizes projected to reach 640.2 billion, 415.7 billion, and 29 billion respectively by 2030 [4] - As young consumers increasingly prioritize standardized services and stable experiences, the competitive landscape is expected to consolidate further, benefiting leading companies [4] Group 4: Business Synergy and Growth Strategy - The company's core business model exhibits significant synergy, utilizing its extensive and trusted beauty services as a front-end traffic source to efficiently convert to higher-priced medical beauty and sub-health services, with cross-business conversion rate reaching 28.7% in 2024 [5] - The company employs a strategy of "directly operated stores as benchmarks, franchising for coverage," leading to rapid expansion of its store network, totaling 554 by the end of 2024 [5] - The company has a mature target selection system and post-acquisition digital integration capabilities, as evidenced by the significant improvement in net profit margin following the acquisition of Nairui'er, validating its strong integration and empowerment capabilities [5]

Core Viewpoint - The report from First Shanghai highlights that Meili Tianyuan Medical Health (02373) is enhancing its operational and integration capabilities through a dual approach of "internal growth + external expansion," with a target price of HKD 43.7 and an initial buy rating [1]. Group 1: Business Model and Ecosystem - Meili Tianyuan has established a "Double Beauty + Double Health" collaborative business model, creating a comprehensive beauty and health ecosystem that includes brands like Meili Tianyuan, Nairui'er, Xiuker, and Yanyuan, covering a full lifecycle of services from high-end beauty to health management [2]. - The core services focus on "lifestyle beauty + medical beauty + sub-health management," guiding customers from lifestyle beauty to high-value medical and health services, thus achieving comprehensive lifecycle management [2]. Group 2: Growth Strategy - The company employs a dual strategy of "internal growth + external expansion" to enhance operational and integration capabilities, utilizing 38 self-developed systems for refined operations, maintaining a customer repurchase rate above 80%, and keeping customer acquisition costs below 2% [3]. - On the external front, the company has made strategic acquisitions of Nairui'er and Siyanli, leveraging strong cash flow to significantly increase membership scale and net profit margins, showcasing strong synergy and integration capabilities [3]. Group 3: Industry Trends - Meili Tianyuan is positioned to lead the transformation of the beauty industry, which is trending towards branding, chain operations, and digitalization, by leveraging its multi-brand strategy, nationwide store network, and advanced digital systems [4]. - The company aims to transition the industry from a fragmented state to a more consolidated and robust structure, enhancing customer value through its "Double Beauty + Double Health" ecosystem [4]. Group 4: Financial Performance - In the first half of 2025, the company reported strong performance with direct store traffic reaching 920,000, a year-on-year increase of 47.8%, and active members rising to 120,000, up 46.5% [5]. - Revenue reached RMB 1,459 million, reflecting a year-on-year growth of 28.2%, while adjusted net profit was RMB 191 million, achieving a record high adjusted net profit margin of 13.1%, demonstrating exceptional profitability resilience amid macro pressures [5]. Group 5: Profit Forecast - The company has significant growth potential driven by both internal growth and acquisition capabilities, with its true growth boundary dependent on management capabilities [6]. - Using a discount rate of 10% and a perpetual growth rate of 3%, the estimated fair value of the company is HKD 10.3 billion, with a target price of HKD 43.7, indicating a potential upside of 65.4% from the previous closing price, corresponding to PE ratios of 29.8 and 24.5 for 2025 and 2026 respectively, thus receiving a buy rating [6].

Core Viewpoint - First Shanghai initiates coverage of Meili Tianyuan Medical Health (02373) with a "Buy" rating and a target price of HKD 43.7, highlighting the company's dual-driven growth strategy of "internal growth + external expansion" [1] Group 1: Business Model - Meili Tianyuan adopts a "Double Beauty + Double Health" collaborative business model, creating a comprehensive health ecosystem that includes brands like Meili Tianyuan, Nairui'er, Xiuker, and Yanyuan, covering a full lifecycle of services from lifestyle beauty to high-end non-surgical medical aesthetics and health management [2] Group 2: Growth Strategy - The company enhances operational and integration capabilities through a dual-driven approach. Internally, it utilizes 38 self-developed systems for refined operations, maintaining a customer repurchase rate above 80% and customer acquisition costs below 2%. Externally, it leverages strong cash flow for strategic acquisitions like Nairui'er and Siyuanli, significantly increasing membership and net profit margins [3] Group 3: Industry Trends - Meili Tianyuan is positioned to lead the transformation of the beauty industry, capitalizing on trends of branding, chain development, and digitalization. Its multi-brand strategy and extensive store network allow it to strengthen its presence in high-tier cities while expanding customer value through the "Double Beauty + Double Health" ecosystem [4] Group 4: Financial Performance - In the first half of 2025, the company reported strong performance with direct store traffic reaching 920,000, a year-on-year increase of 47.8%. Active members grew to 120,000, up 46.5% year-on-year. Total revenue reached RMB 1,459 million, a 28.2% increase, with adjusted net profit at RMB 191 million and an adjusted net profit margin of 13.1%, showcasing robust profitability under macroeconomic pressures [5] Group 5: Valuation - The company has significant growth potential driven by both internal growth and acquisition capabilities. Using a discount rate of 10% and a perpetual growth rate of 3%, the estimated fair value is HKD 10.3 billion, with a target price of HKD 43.7, indicating a 65.4% upside from the previous closing price, corresponding to PE ratios of 29.8 and 24.5 for 2025 and 2026 respectively [6]

Core Viewpoint - The stock price of Beautiful Garden Medical Health (02373.HK) surged by 34.25% on June 4, 2023, reaching a new high of 24.3 HKD per share, driven by positive market sentiment and favorable industry conditions [1][2]. Group 1: Stock Performance - On June 4, 2023, Beautiful Garden Medical Health's stock price increased significantly, closing at 24.3 HKD per share, with a trading volume of 1.6 billion HKD [1]. - The year-to-date increase in the stock price reached 36.52%, surpassing the Hang Seng Index's gain of 17.92% during the same period [1]. Group 2: Market Drivers - The surge in Beautiful Garden Medical Health's stock is attributed to the overall rise in the Hong Kong consumer and medical beauty sectors, with several companies in these sectors hitting historical highs [2]. - The recent boom in the emerging consumer sector is driven by a combination of policy support, holiday effects, and self-care consumption trends [3]. Group 3: Company Developments - Beautiful Garden Medical Health has expanded its brand portfolio, which includes multiple brands such as Beautiful Garden, Beili Shi, and others, focusing on lifestyle beauty, medical beauty, and healthcare [3]. - As of December 31, 2024, the company operates over 554 stores, with 275 being direct-operated and 279 being franchised or managed [3]. - The company announced a plan to acquire an additional 20% stake in Guangzhou Nairui, increasing its ownership to 90%, which is expected to enhance its business model and competitive edge [4]. - Recent shareholder activity, including CITIC Securities' purchase of 147,000 shares, has bolstered market confidence in the company [4].